Abstracts

321 – Association Between Mpox Vaccination and Disease Severity in Washington State, 2023-2025

Background Since the global outbreak in 2022, mpox has continued to circulate worldwide. Previous studies have demonstrated that mpox vaccination can prevent severe disease but have lacked adjustment for differences in age or health status between vaccinated and unvaccinated individuals. Our analysis aimed to compare disease severity among those who were vaccinated to those who…

299 – Characterizing the Autologous CD4bs Antibody Response in HIV-1 Clinical Trial Participants

Background Following HIV infection, autologous antibodies (aAbs) develop against the viral envelope protein (Env). aAbs cannot clear HIV because of Env’s glycosylation patterns and escape mutation toleration. Antiretroviral treatment (ART) suppresses viral replication, but does not eliminate latent reservoirs, underscoring the need for HIV cure. Broadly neutralizing antibodies (bNAbs), which target conserved regions including the…

305 – Safety, Immunogenicity, and Effect on Viral Rebound of T/B-Cell Vaccines in Chronic ART-Treated PWH

Background Vaccine-induced HTI-specific T-cell responses have been associated with extended time off ART in early-treated PWH (etPWH) in 2 independent clinical trials, but with suboptimal viral control. We hypothesized that efficacy of T-cell vaccines could be improved with the support of vaccine-boosted humoral immunity. Methods BCN03 (NCT05208125) was a randomized, placebo-controlled trial testing the safety…

309 – IL-15 Superagonist at ART Initiation Expands SIV-Specific CD8+ T Cells in Blood and Lymphoid Tissues

Background The RV550 clinical trial assessed whether the IL-15 superagonist (IL-15SA) N803 administered alongside ART during acute HIV infection could enhance antiviral immunity and reduce viral persistence. We designed a parallel nonhuman primate study to assess the effects of IL-15SA on viral dynamics and SIV-specific T cell responses in tissues. Methods TwelveMamu A*01+ rhesus macaques (RM),…

1046 – Evaluation of DoxyPEP Consumption in a PrEP Cohort After Structured Counseling

Background Doxycycline post-exposure prophylaxis (doxyPEP) is an effective strategy to prevent bacterial sexually transmitted infections (bSTIs). However, concerns that high antibiotic consumption may drive antimicrobial resistance have limited its implementation. We evaluated doxyPEP use and actual doxycycline consumption in a cohort of HIV pre-exposure prophylaxis (PrEP) users. Methods We conducted a retrospective analysis of all…

330 – Proviral Genetic Barcoding Tracks CD4+ T-Cell Transitions With Novel Intact HIV-1 Provirus Clones

Background The majority of proviral DNA sequences are defective due to deletions and mutations in open reading frames. Defects in non-coding regions can also render proviruses defective; such proviruses may appear structurally intact yet potentially lack full competence. In this study, we identified such defective proviruses in two participants followed for 30 years and used…

624 – Twenty-Six-Year Kaposi Sarcoma Incidence and Mortality Trends in the Population-Based PISCIS Cohort

Background Kaposi sarcoma (KS) remains an important AIDS-defining malignancy in the antiretroviral therapy (ART) era, yet its contemporary epidemiology and outcomes are not well characterized. Methods Population-based cohort study in Catalonia, Spain, including all adult with HIV (PWH) in the PISCIS Cohort (1998–2023) without prior KS. We estimated KS incidence rates (IR), and all-cause mortality rates (MR) after…

383 – CARD8 Activation by Efavirenz Intensification for Reservoir Reduction

Background HIV-1 persists primarily in memory CD4+ T cells. The CARD8 inflammasome is an innate immune sensor which can be activated by viral protease activity to induce pyroptosis in HIV-1-infected cells. Our recent studies demonstrate that some NNRTIs including Efavirenz (EFV) drive intracellular Gag-Pol dimerization, which then forces premature viral protease activation. Induction of this…